Kornimate/medical-research-clean huggingface dataset:
incorporating narrative into the treatment of youth with anorexia nervosa

Conditions: Anorexia Nervosa

Summary: the goal of this clinical trial is to evaluate whether a narrative medicine (nm) curriculum can enhance self-expression, reflection, and resilience in adolescents and young adults with anorexia nervosa. the main questions it aims to answer are: * does participation in an nm curriculum improve self-expression and reflection in individuals with anorexia nervosa? * does engaging in creative writing and group discussion promote resilience and emotional processing in this population? participants will be 16-25 years old, medically stable for outpatient eating disorder therapy, and actively engaged in treatment. those with active suicidal ideation, recent non-suicidal self-injury, or a co-occurring personality disorder will not be eligible. participants will: * attend six weekly workshops (april-may 2025) focused on themes such as self-definition, kindness, resilience, and possibility * engage in close reading of visual or written texts * complete creative writing exercises in response to prompts * participate in group discussions and sharing an optional capstone reading event will provide a supportive space for participants to share their work with peers, loved ones, and providers, fostering connection and community. this study aims to explore the role of narrative medicine in eating disorder treatment and assess its potential benefits for psychological well-being and self-expression.


Eligibility criteria:
inclusion criteria: * 16-25 years old * have a dsm-5 diagnosis of an (confirmed by the ucsf eating disorders program clinical team), * currently engaged in outpatient eating disorder treatment, ensuring medical stability and capacity for a group-based intervention * english fluency to engage in reflective writing and discussions * cognitive ability to meaningfully participate in narrative-based exercises exclusion criteria: * currently medically unstable or require inpatient hospitalization * history of psychosis, schizophrenia spectrum disorder, bipolar disorder, or personality disorder * severe neurocognitive impairment that would prevent engagement with the intervention * active suicidal ideation or non-suicidal self-injury within the past two months * insufficient english proficiency to participate in group discussions and writing exercises
efficacy and safety of ql0911 in adult patients with chronic primary immune thrombocytopenia

Conditions: Primary Immune Thrombocytopenia

Summary: ql0911, a recombinant human thrombopoietin mimetic peptide-fc fusion protein for injection, is a romiplostim (nplate®) biosimilar for the treatment of primary immune thrombocytopenia (itp). this phase iii study aimed to assess the efficacy and safety of ql0911 in adult patients with primary chronic itp.

this study consisted of a randomized, double-blind, placebo-controlled, 26-week treatment period, sequentially followed by an open-label, single-arm, 12-week treatment period, and an additional 4-week safety follow-up period.

Eligibility criteria:
inclusion criteria: * aged ≥18 years old; * diagnosed primary itp for at least 12 months; * had received at least one first-line itp treatment with no response or recurrence after treatment; * had a platelet count \<30×10\^9/l within 48 hours before the first dose; * eastern cooperative oncology group (ecog) performance status of 0, 1, or 2; * fully understand and comply with the requirements of this study, and voluntarily sign the informed consent form. exclusion criteria: * had a history of bone marrow stem cell abnormalities or myelodysplastic syndrome other than itp-specific changes. * had arterial thrombosis, or venous thromboembolism; severe cardiovascular diseases; malignant tumors; secondary thrombocytopenia caused by autoimmune diseases. * underwent splenectomy within 12 weeks before the first dose; * had received itp treatments (including rescue treatment) within 2 weeks before the first dose; * had received romiplostim (nplate®) or eltrombopag (revolade®), rhtpo or other agents that stimulate tpo receptors (also known as c-mpl), and hematopoietic growth factors (hgfs) within 4 weeks before the first dose; * had received antineoplastic agents within 8 weeks before the first administration, but when treating itp with hypomethylating agents (hma) such as decitabine, a 4-week washout period was acceptable, as judged by the investigator; * had received antibody-based therapies within 14 weeks before the first dose; 8) had serum creatinine or total bilirubin \>1.5 upper limit of normal (uln), alanine transaminase (alt) or aspartate transaminase (ast) \>3 uln, hemoglobin \< 100g/l, absolute neutrophil count \<1.5x10\^9/l; * had prothrombin time (pt) or prothrombin time-international normalized ratio (pt-inr) or activated partial thromboplastin time (aptt) exceeded 20% of the reference range of normal values.
covid-19 infection and reproductive health in infertile women

Conditions: Infertility, Female

Summary: an increased number of women has been infected by covid-19 in the last 2 years sars-cov-2 infection could have a role in potential disturbances on hormon levels and human fertility has not completely demonstrated covid-19 effects on female reproductive function and further research can be undertaken. the proposed multicenter study will be simple and rapid, and attractive for the scientific community.

covid-19 virus is classified as a respiratory disease that drastically changed our daily life and perspective (1) can be mainly transmitted via respiratory droplets, however, there are recently published reports suggested its ability to transmit via sexual intercourse, assisted reproductive technology (art) treatments, pregnancy, and nursing. art specialists should be precautious, carefully following the situation while contributing by sharing novel evidence to counsel our patients (2). however, there are no comprehensive reviews to explore the association between covid-19 and female fertility comprehensively.its of major importance to provide in-depth research explaining the underlying mechanism of sars-cov-2 infection and its impact on human reproductive organs and fertility (3). ovarian reserve is a key determinant of female fertility. in this study we observe the potential effects of sars-cov-2 infection on the principal indicators of ovarian reserve function as anti-müllerian hormone (amh); basal follicle-stimulating hormone (fsh), basal luteinising hormone (lh) basal oestradiol (e2) antral follicle count (afc). questions regarding the potential risks of sexual transmission during intercourse and/or application of art, vertical transmission (throughout pregnancy, delivery, and breastfeeding), the health of pregnant and postpartum women, and fetal or postnatal health problems of neonates/children remain largely unanswered (4,5).

Eligibility criteria:
inclusion criteria: women 24-43 years of age previous history of covid-19 infection infertility diagnosis exclusion criteria: women with current symptoms of covid-19 infection positive for hiv or the presence of active viral hepatitis previosuly ovarian cancer, removal of ovaries or gonadotoxic treatments

Keywords: sars cov 19,ivf,ovarina reserve,pregnancy
determination of dosing and frequency of bcg administration to alter t-lymphocyte profiles in type i diabetics

Conditions: Type 1 Diabetes Mellitus

Summary: type 1 diabetes is caused by an autoimmune destruction of the insulin producing cells of the pancreas. the investigators have discovered the specific autoimmune cells responsible for destroying the insulin-producing cells in an animal model of type 1 diabetes, and the means of destroying those cells.

the investigators are now aiming to use a similar strategy (vaccination with bcg, the vaccine used world-wide to protect against tuberculosis) in human type 1 diabetes to see if the abnormal immune cells can be depleted. this is the first step in trying to cure established type 1 diabetes.

Eligibility criteria:
inclusion criteria (type 1 diabetic subjects): * type 1 diabetes treated continuously with insulin from time of diagnosis * age 18-55 * anti-gad positive * hiv antibody negative * normal cbc * negative intermediate ppd test performed and read by study staff * hcg negative (females) exclusion criteria type 1 diabetic subjects): * history of chronic infectious disease, such as hiv * history of tuberculosis, tb risk factors, or history of + ppd, or bcg vaccination * treatment with glucocorticoids (other than intermittent nasal steroids) or disease or condition likely to require steroid therapy * other conditions or treatments associated with increased risk of infections such as patients with previous history of severe burns, or treatment with immunosuppressive medications of any type (e.g. imuran, methotrexate, cyclosporine, etanercept, infliximab) for any reason * current treatment with aspirin \> 160 mg/day or chronic, daily nsaids * fasting or stimulated (1 mg glucagon stimulation test) c-peptide \> 0.2 pmol/ml * history of keloid formation * hba1c \> 8.0% * history or evidence of chronic kidney disease (serum creatinine \> 1.5 mg/dl) * history of proliferative diabetic retinopathy that has not been treated with laser therapy * pregnant or not using acceptable birth control * living with someone who is immunosuppressed and/or at high risk for infectious diseases (for example hiv+ or taking immunosuppressive medications for any reason). inclusion criteria (control non-diabetic subjects): * age 18-45 exclusion criteria (control non-diabetic subjects): * history of autoimmune diseases or diabetes * history of hiv history of autoimmune disease or type 1 diabetes (use of insulin continuously since diagnosis) in first degree family members

Keywords: type 1 diabetes mellitus immune modulation cure autoimmunity
impact of real-time automatic quality control system on colorectal adenoma detection

Conditions: Colonoscopy

Summary: the purpose of this study was to assess the performance of automatic quality-control system (aqcs) in real-time quality control of colonoscopy.

we carried a multicenter randomised controlled trial to assess the performance of this system in quality control of real-time colonoscopy, including the adenoma detection rate (adr), withdraw time, adequate bowel preparation rate and other indicators.

Eligibility criteria:
inclusion criteria: * consecutive patients (aged 18-80 years) scheduled for colonoscopy examination. exclusion criteria: * patients with a history of inflammatory bowel disease, advanced colorectal cancer, polyposis syndromes or known colorectal polyps without complete removal previously. * patients with a history of colorectal surgery. * patients with a contraindication for biopsy. * patients with prior failed colonoscopy. * patients with known stenosis or obstruction. * patients in pregnancy or lactation phase. * patients refused to participate in the trial.

Keywords: artificial intelligence colonoscopy quality control
free nonvascularized fibula autograft for tumor-like lesions in femoral neck using in pediatric patients

Conditions: Bone Diseases

Summary: this study was to evaluate the safety and efficacy of free nonvascularized fibula autograft in the treatment of the femoral neck tumor-like lesions before epiphyseal closure in pediatric patients, by presenting the clinic-radiological outcome and complications.


Eligibility criteria:
inclusion criteria: 1. this retrospective study included pediatric patients before epiphyseal closure with tumor-like lesions in femoral neck. exclusion criteria: 1. pediatric patients with tumor-like lesions in femoral neck after epiphyseal closure; 2. pediatric patients with benign bone tumors and malignant bone tumors in the femoral neck after epiphyseal closure; 3. adult patients with benign or malignant bone tumors and tumor-like lesions in femoral neck.
effect of aerosol filtering on infectious diseases in day care

Conditions: Upper Respiratory Tract Infection; Diarrhea

Summary: effect of aerosol flitration and removal on typical infectious diseases such as upper respiratory tract infectinos is studied in day care. many filtration methods such as filters and electrical filtering are used to remove aerosol particles from room air.


Eligibility criteria:
inclusion criteria: * subject is expected to be in the same day care unit for the duration of the study exclusion criteria: * subject is known not to be in the same day care unit for the duration of the study
the effect of astym treatment on muscle performance

Conditions: Musculoskeletal Pathology to the Lower Extremity

Summary: subjects were randomized into 3 treatment groups (15 subjects per group): 1) control - received no treatment 2) placebo - received a sham astym® treatment 3) astym® treatment - received astym® treatment to the lower extremity. subjects were blinded to whether they received the astym® treatment or placebo treatment intervention. after a 5-minute warm-up on a lower body ergometer the subjects were familiarized to the operations of a computerized leg press machine that measured the maximum force output (newtons) during a unilateral isometric squat test. a baseline measure of maximal force output (pre-test) was determined by the average of 3 trials with a 30 second rest period between the trials. the subjects then received the designated treatment intervention. immediately following the treatment intervention (0 minutes following treatment intervention) the subjects were retested (post-test) using identical testing procedures by an investigator blinded to the treatment intervention received by the subject. maximum force output measured in newtons for the post-test was subtracted from the maximum force output (newtons) pre-test and then converted to a percentage of change \[(post-test - pretest)/pretest x 100). the percent change of maximal force output from pre-test to post-test measures was compared using a one-way analysis of variance with alpha set at 0.05. a tukey's post-hoc analysis determined statistical differences between the groups.


Eligibility criteria:
inclusion criteria: 1. referral for physical therapy services to the student investigator for a musculoskeletal injury to the lower extremity. 2. subjects must be aged between 18-65 years-old 3. present with a 10% or greater deficit in maximum force output on computerized leg press machine when compared to the uninvolved side 4. able to read and understand english language. 5. read, comprehend, and sign informed consent procedures. exclusion criteria: 1. subjects who are pregnant 2. subjects with a medical history of hemophilia or other clotting disorders of the blood 3. subjects currently taking blood thinners (e.g. lovenox, coumadin) 4. subjects with neuropathy of the lower extremity 5. subjects with a history of metastatic disease 6. subjects with uncontrolled hypertension 7. subjects that are unable to perform the strength test due to the nature of injury 8. subjects with a recent history (within the past 4 weeks) of lower extremity surgery. 9. subjects with compromised skin integrity. (e.g. open wounds, diabetic ulcers, lacerations, abrasions) 10. subjects with any sign of infection including skin infections to the lower limbs.
methodology for developing an occlusal appliance with cbd active carrier

Conditions: Temporomandibular Disorder; Myofascial Pain; Cannabis; Electromyography; Occlusal Appliance; CBD

Summary: evaluation of the efficacy of the occlusal appliance with active cannabidiol (cbd) molecules in tmd patients

occlusal appliance therapies are used in tmd patients. in this research the active cbd molecules will be released from the occlusal appliance during nighttime, in population of patients suffering from tmd. the effectiveness of the myorelaxation (semg of mastcatory muscles activity) and analgesic effect( vas analysis) of occlusal appliance with the cbd molecules will be compared to the traditional acrylic-resin material used so far for occlusal appliance manufacture. the aim of the research is the evaluation of the innovative material effectiveness, used for the production of the occlusal appliance.

Eligibility criteria:
inclusion criteria: * patient agreement to take part in the study * rdc/tmd group ia and ib * bruxism index\> 3 ( brux-off polysomnography) exclusion criteria: * cbd allergy/hypersensitivity/ addiction * therapy with analgesic drugs * therapy with drugs affecting muscle function * fixed or removable dental prosthesis * ongoing orthodontic treatment * other general disorders affecting muscle tension

Keywords: temporomandibular disorder myofascial pain cannabis electromyography occlusal appliance cbd
post approval study of the acrysof® iq restor® toric iols

Conditions: Aphakia; Presbyopia; Astigmatism

Summary: this is a prospective, multicenter, post-approval active surveillance study. the purpose of this study is to report the rate of post-surgical intraocular inflammation (based upon a specified case definition) reported within a 180-day post-surgical period following attempted implantation of an acrysof iq restor toric or acrysof iq restor iol in the us.

if a second eye will participate in the study, subjects will receive the second eye cataract surgery within 20 days of the first eye surgery. four postoperative follow-up visits are planned to occur at 1-2 days, 7-14 days, 30-60 days, and 90-180 days, for each enrolled eye. subject participation in this study is expected to last up to 7 months, including a total of 6 study visits for subjects implanted in one eye and up to 11 visits for subjects implanted in both eyes. upon completion of the 180 days follow-up visit, subjects will be exited from the study.

Eligibility criteria:
inclusion criteria: * preoperative cataract in the study eye(s) * planned implantation in at least one eye with: * cohort 1: an acrysof iq restor +3.0 d multifocal toric iol (models snd1t3, snd1t4, snd1t5 or snd1t6) or an acrysof iq restor +2.5 d multifocal toric iols (models sv25t3, sv25t4, sv25t5, and sv25t6) in accordance with the product labeling from november 2018 to july 2020 * cohort 2: an acrysof iq restor +3.0 d multifocal toric iol (models snd1t3, snd1t4, snd1t5 or snd1t6), or an acrysof iq restor +2.5 d multifocal iol (model sv25t0) in accordance with the product labeling after july 2020. * able to comprehend and sign a statement of informed consent * willing and able to complete all required postoperative visits * other protocol-specified inclusion criteria may apply. exclusion criteria: * eyes with clinically significant ocular, including adnexa, or intraocular infection or inflammation (at the screening visit prior to surgery or on the day of surgery) * history of any intraocular inflammation within the past 12 months (ex: uveitis, choroiditis) * combined procedures introducing an additional medical device during cataract surgery (ex: cataract surgery with implant of glaucoma stent) * other protocol-specified exclusion criteria may apply.

Keywords: cataract
retrospective data analysis of vitalcare targeted population management on scott and white chronically ill beneficiaries

Conditions: Chronic Illness

Summary: new payment methods such as accountable care organization (aco's) and medical homes facilitate are new models for providers to deliver cost effective, quality patient outcomes. integrated care coaching (icc) is a healthcare delivery model combining telephonic interventions with an intelligent information technology platform that offered validated protocols and patient outcomes tracking. health integrated, inc. has developed a validated program of integrated care coaching (icc), which was branded as "vitalcare", and implemented with over 7,000 members of the scott and white health plan in texas, would reduce healthcare costs/achieve a return on investment (roi), improve clinical outcomes, and be satisfying for participants.

a prospective, pre-post historical control design trial with a concurrent control group cost/satisfaction analysis with a retrospective clinical study was undertaken with adult, scott and white health plan (swhp) patients with chronic illnesses. from 2007 to 2010, a total of 7,411 icc and 10,148 control patients participated. variables were costs, return on investment (roi), iterative patient health questionnaire (phq)9 scores, and satisfaction.

Eligibility criteria:
inclusion criteria: * 18 years or older * having one or more of 21 chronic conditions, including those with depression and multiple chronic comorbidities. exclusion criteria: * presence of major cancer, hiv, or esrd in either the baseline or measurement periods * claims in excess of $100,000 in either baseline or intervention period. * claims for long term care or hospice in either baseline or intervention period.

Keywords: integrated care coaching chronic care coaching care coaching
clinic registry study of optic neuromyelitis spectrum disease in china

Conditions: NMO Spectrum Disorder;Registry Study

Summary: in 1894, devic first proposed the concept of neuromyelitis optica(nmo). nmo is an inflammatory demyelinating disease that selectively affects the central nervous system of the optic nerve and spinal cord.in 2004, lennon and other persons found highly specific aqp4（aquaporin 4）antibodies in nmo patients'sera, and further differentiated between nmo and ms, confirming that nmo is an independent disease.at present, nmo has been widely recognized as an idiopathic and severe demyelinating disease of the central nervous system.in 2015, the international nmo diagnostic team developed the diagnostic criteria based on highly specific aqp4 antibodie.up to now, in china, there is no data on the number of nmosd patients, the rate of misdiagnosis, the treatment methods, and the prognosis.this study is committed to build china's nmosd big data platform to provide the basis for diagnosis, treatment and prognosis of the disease.


Eligibility criteria:
inclusion criteria: 1. more than 14 years old 2. compliance with the diagnostic standard by the nmo international diagnostic team in 2015 exclusion criteria: 1. less than 14 years old 2. not compliance with the diagnostic standard by the nmo international diagnostic team in 2015
hemodilution and coagulopathy with 3 colloids

Conditions: Dilutional Coagulopathy

Summary: aim of this in vitro trial is to assess the effect on blood coagulation after 60 % dilution with different colloids (hes 130/0.42, gelatin and gelatin balanced) and investigate reversibility by replacement of fibrinogen (fbg), factor xiii (f xiii), and the combination of fbg and fxiii. in blood of 12 volunteers the following measurements are performed at baseline and 60% dilution with hes 130/0.42, gelatin or gelatin balanced: blood gas analyses, coagulation factor concentrations (f ii,f vii,f viii,f xiii), impedance aggregometry and rotational thrombelastometry (rotem®). then fbg, f xiii and a combination of both was added, in concentrations corresponding to 6 g fbg and 1250 iu f xiii in adults. rotem® measurements and determination of factor concentrations are again performed. * trial with medical device


Eligibility criteria:
inclusion criteria: * signed informed consent from before blood withdrawal exclusion criteria: * known coagulation disorders, * any form of anticoagulation therapy, * use of acetyl-salicylic acid within the past five days, * use of non-steroidal anti-inflammatory agents within the past 24 hours, * known renal disease or plasma concentrations of aspartate aminotransferase (\>50 u l -1) or alanine aminotransferase (\>50 u l-1) * patients incapable of understanding the german language